{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:48:45Z","timestamp":1792097325236,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["RCU_H_64_017_30"],"award-info":[{"award-number":["RCU_H_64_017_30"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.biopha.2024.116142","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:06:02Z","timestamp":1704809162000},"page":"116142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Anticancer effect of zoledronic acid in endocrine-resistant breast cancer cells via HER-2 signaling"],"prefix":"10.1016","volume":"171","author":[{"given":"Patthamapon","family":"Adchariyasakulchai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1759-5974","authenticated-orcid":false,"given":"Nithidol","family":"Sakunrangsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5764-071X","authenticated-orcid":false,"given":"Sarun","family":"Chokyakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayanin","family":"Suksanong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-5750","authenticated-orcid":false,"given":"Wannarasmi","family":"Ketchart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116142_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107369","article-title":"Disruption of the ER-\u03b136-EGFR\/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells","volume":"9","author":"Yin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.116142_bib2","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2024.116142_bib3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: a review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116142_bib4","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2024.116142_bib5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.6004\/jnccn.2015.0061","article-title":"Routine use of zoledronic acid in early-stage breast cancer","volume":"13","author":"Harnden","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.biopha.2024.116142_bib6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.canlet.2006.03.011","article-title":"Differential effects of bisphosphonates on breast cancer cell lines","volume":"246","author":"Verdijk","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2024.116142_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jbo.2013.12.001","article-title":"The anti-tumour effects of zoledronic acid","volume":"3","author":"Zekri","year":"2014","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.biopha.2024.116142_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2024.116142_bib9","doi-asserted-by":"crossref","first-page":"17989","DOI":"10.1073\/pnas.1421410111","article-title":"Bisphosphonates inactivate human EGFRs to exert antitumor actions","volume":"111","author":"Yuen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2024.116142_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2184.2011.00745.x","article-title":"Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line","volume":"44","author":"Di Salvatore","year":"2011","journal-title":"Cell Prolif."},{"key":"10.1016\/j.biopha.2024.116142_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172878","article-title":"Plumbagin inhibited AKT signaling pathway in HER-2 overexpressed-endocrine resistant breast cancer cells","volume":"868","author":"Sakunrangsit","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116142_bib12","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/sj.bjc.6605579","article-title":"Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction","volume":"102","author":"Neville-Webbe","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116142_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185566","article-title":"Estradiol impairs the antiproliferative and proapoptotic effect of zoledronic acid in hormone sensitive breast cancer cells in vitro","volume":"12","author":"Gschwantler-Kaulich","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.116142_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.clinthera.2018.03.004","article-title":"Progression-free survival with first-line endocrine-based therapies among postmenopausal women with HR+\/HER2- metastatic breast cancer: a network meta-analysis","volume":"40","author":"Ayyagari","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2024.116142_bib15","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1002\/cncr.23875","article-title":"Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions","volume":"113","author":"Hurvitz","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2024.116142_bib16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0960-9776(03)00137-1","article-title":"Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer","volume":"12","author":"Osborne","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.biopha.2024.116142_bib17","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djz215","article-title":"Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307","volume":"112","author":"Gralow","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2024.116142_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1302\/2046-3758.63.BJR-2016-0125.R1","article-title":"Bisphosphonates and atypical subtrochanteric fractures of the femur","volume":"6","author":"Kharwadkar","year":"2017","journal-title":"Bone Jt. Res."},{"key":"10.1016\/j.biopha.2024.116142_bib19","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","article-title":"Bisphosphanates and oral cavity avascular bone necrosis","volume":"21","author":"Migliorati","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116142_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1475-2867-12-48","article-title":"Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid","volume":"12","author":"Ibrahim","year":"2012","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.biopha.2024.116142_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216908","article-title":"Heteromerization fingerprints between bradykinin B2 and thromboxane TP receptors in native cells","volume":"14","author":"Dagher","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.116142_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2024.116142_bib23","article-title":"Perspectives, analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2024.116142_bib24","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/ptr.5702","article-title":"Plumbagin enhances tamoxifen sensitivity and inhibits tumor invasion in endocrine resistant breast cancer through EMT regulation","volume":"30","author":"Sakunrangsit","year":"2016","journal-title":"Phytother. Res."},{"key":"10.1016\/j.biopha.2024.116142_bib25","article-title":"Zoledronic acid inhibits the growth of cancer stem cell derived from cervical cancer cell by attenuating their stemness phenotype and inducing apoptosis and cell cycle arrest through the ERK1\/2 and Akt pathways","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2024.116142_bib26","doi-asserted-by":"crossref","first-page":"17995","DOI":"10.1073\/pnas.1421422111","article-title":"Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer","volume":"111","author":"Stachnik","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2024.116142_bib27","doi-asserted-by":"crossref","first-page":"29321","DOI":"10.18632\/oncotarget.8722","article-title":"Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?","volume":"7","author":"Fanale","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116142_bib28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s12032-011-9904-1","article-title":"Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells","volume":"29","author":"Li","year":"2012","journal-title":"Med. Oncol."},{"key":"10.1016\/j.biopha.2024.116142_bib29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1023781114568","article-title":"Role of MAP kinase in tumor progression and invasion","volume":"22","author":"Reddy","year":"2003","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.biopha.2024.116142_bib30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.0.CO;2-4","article-title":"Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells","volume":"82","author":"Reddy","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116142_bib31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/ijms14010108","article-title":"Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance","volume":"14","author":"Garc\u00eda-Becerra","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116142_bib32","first-page":"203","article-title":"Clinical potential of novel therapeutic targets in breast cancer: CDK4\/6, Src, JAK\/STAT, PARP, HDAC, and PI3K\/AKT\/mTOR pathways","volume":"7","author":"Hosford","year":"2014","journal-title":"Pharmgenom. Pers. Med."},{"key":"10.1016\/j.biopha.2024.116142_bib33","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1074\/jbc.271.14.7992","article-title":"Oncogenic Neu\/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation","volume":"271","author":"Galang","year":"1996","journal-title":"J. Biol. Chem."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224000234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224000234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:40:53Z","timestamp":1792096853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224000234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":33,"alternative-id":["S0753332224000234"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116142","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer effect of zoledronic acid in endocrine-resistant breast cancer cells via HER-2 signaling","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116142"}}